Amylina"; integrated diabetes medicine to ease consumption and make patients cheaper.
By producing the combined drug "Amelina", Ofogh Daru provided three active ingredients empagliflozin, lingliptin and metformin in the form of a pharmaceutical product for patients with type 2 diabetes.
Through the multi-layered formulation and the controlled release technology of metformin, this drug provides the possibility of a gradual release of this effective substance in about 10 hours.
The average weight of Amelin tablets compared to similar samples made it easier for patients, especially the elderly, to swallow it.
This product is covered by insurance and it is estimated that about 90% of its cost will be paid by the insurance companies. Its price is much lower compared to foreign models.